Encorafenib plus binimetinib combined BRAF-MEK inhibitors  

     

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultdeath (overall survival) progression or death (progression free survival PFS)

melanoma  

COLUMBUS, 2018      NCTencorafenib plus binimetinibvemurafenib1LRisk of bias suggesting-46%